Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research
Much of our knowledge of the endocannabinoid system in schizophrenia comes from behavioral measures in rodents, like prepulse inhibition of the acoustic startle and open-field locomotion, which are commonly used along with neurochemical approaches or drug challenge designs. Such methods continue to...
Saved in:
Main Authors: | Rafael N. Ruggiero (Author), Matheus T. Rossignoli (Author), Jana B. De Ross (Author), Jaime E. C. Hallak (Author), Joao P. Leite (Author), Lezio S. Bueno-Junior (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2017-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of Cannabinoid Drugs on the Deficit of Prepulse Inhibition of Startle in an Animal Model of Schizophrenia: the SHR Strain
by: Raquel eLevin, et al.
Published: (2014) -
Cannabidiol, among other cannabinoid drugs, modulates prepulse inhibition of startle in the SHR animal model: implications for schizophrenia pharmacotherapy
by: Fernanda Fiel Peres, et al.
Published: (2016) -
Direct activation of Transient Receptor Potential Vanilloid 1(TRPV1) by Diacylglycerol (DAG)
by: Oh Seog, et al.
Published: (2008) -
Lack of the Transient Receptor Potential Vanilloid 1 Shifts Cannabinoid-Dependent Excitatory Synaptic Plasticity in the Dentate Gyrus of the Mouse Brain Hippocampus
by: Jon Egaña-Huguet, et al.
Published: (2021) -
Is Cannabidiol During Neurodevelopment a Promising Therapy for Schizophrenia and Autism Spectrum Disorders?
by: Cássio Morais Loss, et al.
Published: (2021)